Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial

Sian Robinson, Aleksander Zincuk, Thomas Strøm, Torben Bjerregaard Larsen, Bjarne Rasmussen, Palle Toft

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

ABSTRACT: INTRODUCTION: Intensive care unit (ICU) patients are predisposed to thromboembolism. Routine prophylactic anticoagulation is widely recommended. Low-molecular-weight heparins, such as enoxaparin, are increasingly used because of predictable pharmacokinetics. This study aims to determine the subcutaneous (SC) dose of enoxaparin that would give the best anti-factor Xa levels in ICU patients. METHODS: The 72 patients admitted to a mixed ICU at Odense University Hospital (OUH) in Denmark were randomised into four groups to receive 40, 50, 60, or 70 mg SC enoxaparin for a period of 24 hours. Anti-factor Xa activity (aFXa) was measured before, and at 4, 12, and 24 hours after administration. An AFXa level between 0.1 to 0.3 IU/ml was considered evidence of effective antithrombotic activity. RESULTS: Median peak (4 hours after administration), aFXa levels increased significantly with an increase in enoxaparin dose, from 0.13 IU/ml at 40 mg, to 0.14 IU/ml at 50 mg, 0.27 IU/ml at 60 mg, and 0.29 IU/ml at 70 mg (P = 0.002). At 12 hours after administration, median aFXa levels were still within therapeutic range for those patients who received 60 mg (P = 0.02). CONCLUSIONS: Our study confirmed that a standard dose of 40 mg enoxaparin yielded subtherapeutic levels of aFXa in critically ill patients. Higher doses resulted in better peak aFXa levels, with a ceiling effect observed at 60 mg. The present study seems to suggest inadequate dosage as one of the possible mechanisms for the higher failure rate of enoxaparin in ICU patients. TRIAL REGISTRATION: ISRCTN03037804.
Original languageEnglish
JournalCritical Care (Online Edition)
Volume14
Issue number2
Pages (from-to)R41
ISSN1466-609X
DOIs
Publication statusPublished - 18. Mar 2010

Fingerprint

Dive into the research topics of 'Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial'. Together they form a unique fingerprint.

Cite this